Clinical trial
CAFE Comparison of Atypicals in First Episode of Psychosis
NCT00034892 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00034892 |
|---|---|
| Title | CAFE Comparison of Atypicals in First Episode of Psychosis |
| Official title | Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomized Double Blind 52-Week Comparison |
| Lead sponsor | AstraZeneca, Industry |
| Collaborators | University of North Carolina |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia, Psychotic Disorders, Mental Health, Mental Disorders |
| Intervention type | Drug |
| Interventions | Olanzapine, risperidone |
| Start date | Mar 1, 2002 |
| Primary completion | Mar 1, 2005 |
| Completion | Mar 1, 2005 |
| First posted | May 3, 2002 |
| Last update posted | Jan 4, 2013 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: